ACI’s 10th Anniversary Paragraph IV Disputes Master Symposium

https://www.thefdalawblog.com/2024/07/acis-10th-anniversary-paragraph-iv-disputes-master-symposium/?utm_source=rss&utm_medium=rss&utm_campaign=acis-10th-anniversary-paragraph-iv-disputes-master-symposium The American Conference Institute (“ACI”) is holding its 10th Anniversary Paragraph IV Disputes Master Symposium from October 15-16, 2024, at the Hyatt Regency McCormick Place in Chicago, Illinois. Each fall, leading pharmaceutical patent litigators for brand-name and generic drug companies gather at the Paragraph IV Disputes Master Symposium in Chicago to receive up-to-the-minute information on the latest developments affecting Hatch-Waxman litigation and participate in significant peer-to-peer networking opportunities. Join us to address emerging and growing areas of concern, including the implementation of the Inflation Reduction Act, FTC’s—and now a District Court’s—attack on Orange Book patent listings, and the proposed use of the Bayh Doyle Act. Other key program highlights this year include: Examining the Use of Clinical Trials as Prior Art: How to Thread the Needle on Protecting IP and Mandated Disclosures Patent Rights and Supply Chain Dynamics: Understanding How Developments in India May Affect Hatch-Waxman- Generic and Brand Perspectives Fireside Chat on Future of FDA Initiatives Affect Small Molecules: Regulatory Initiatives, and Agency Developments for Hatch Waxman Practitioners to Watch Hyman, Phelps & McNamara, P.C.’s Kurt R. Karst will moderate a panel discussion, titled “Fireside Chat on the Future of the FDA: Regulatory Initiatives, and Agency Developments for Hatch Waxman Practitioners to Watch.” https://www.americanconference.com/paragraph-iv-disputes-master-symposium/?utm_medium=affiliate&utm_source=fdalawblog&utm_campaign=F25_awareness